Sermoreln
$50.00
5mg of reagent-grade Sermoreln.
Third Party Verified
Third Party Verified
Description
Product Summary – Sermoreln – Fragment of GHRH
| Field | Details |
| Product Name | Sermoreln (GRF 1–29 NH₂) |
| Category | Synthetic peptide analog of growth hormone–releasing hormone (GHRH); originally used for diagnostic evaluation of GH secretion |
| Length | 29 amino acids (C-terminal fragment of native 44-aa GHRH) |
| Amino Acid Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ |
| Molecular Formula | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Molecular Weight | ≈ 3357.9 Da |
| Form & Purity | Lyophilized peptide powder for injection; ≥95% purity (HPLC, vendor spec). |
| Storage | Store at −20 °C (unreconstituted). Protect from light and moisture. Reconstituted solutions should be refrigerated (2–8 °C) and used within a short period; avoid repeated freeze–thaw cycles. |
| Typical Dose (historical/ diagnostic use) | 0.5 µg/kg SC or IV bolus for GH stimulation testing in children with suspected GH deficiency (withdrawn from market in 2008). |
| Key Mechanisms | – Binds pituitary GHRH receptors → stimulates endogenous GH release
– GH rise → increases hepatic IGF-1 production – Mimics physiologic pulsatile GH release better than exogenous GH administration |
| Research / Clinical Use Cases | – Historically FDA-approved for pediatric GH deficiency diagnosis
– Investigated in adults for GH deficiency, aging-related GH decline, body composition, and sleep quality – Research interest in neuroprotection and immune modulation |
| Common AEs / Safety Signals | – Transient flushing, injection-site reactions, headache
– Rare: dizziness, nausea, altered taste – Elevated GH/IGF-1 levels may pose long-term theoretical risk (e.g., neoplasia, insulin resistance) |
| Contraindications / Warnings | – Known hypersensitivity
– Use caution in patients with active malignancy (due to GH/IGF-1 axis stimulation) |
| Regulatory / Compliance | – FDA-approved (1997–2008) for GH deficiency diagnosis in children
– Withdrawn from the U.S. market in 2008 for commercial reasons (not safety-related) – Currently available only via research supply or compounding pharmacies; not an FDA-approved therapeutic |
Mechanism of Action of Sermoreln
GH Secretion
Sermoreln, upon systemic administration, binds to the extracellular domain of pituitary GHRHR and couples to the GPCR, mirroring the endogenous GHRH. It causes the prompt and dose-dependent release of GH, preserving the physiological negative feedback through lIGF-1 and somatostatin. [1]
Axis-Level Integration and Feedback
At the hypothalamic–pituitary level, sermoreln interacts with endogenous regulators such as somatostatin, which inhibits cAMP signaling and suppresses GH release, and ghrelin/GHS-R1a signaling, which acts synergistically with GHRHR. When both sermoreln and ghrelin pathways are co-activated, they amplify cAMP production and enhance GH secretion.
GH-driven hepatic IGF-1 induces negative feedback at both the hypothalamus and pituitary, preserving the ultradian GH pulsatility. That is the reason that explains why sermoreln exerts physiological and feedback-limited GH excursions rather than tonic hypersecretion. [3]
Tolerability and Safety Considerations of Sermoreln
- Most adverse events are mild (injection-site pain, redness, or swelling).
- Possible fluid retention and arthralgia, especially at higher doses.
- Anti-GHRH antibodies may develop, but usually do not affect efficacy or safety.
- Hypothyroidism can occur or reduce treatment response; glucocorticoids blunt GH release.
- Minimal impact on glucose homeostasis, but monitor insulin/glucose in at-risk patients.
Citations
- Montero-Hidalgo, A. J., Del Rio-Moreno, M., Pérez-Gómez, J. M., Luque, R. M., & Kineman, R. D. (2025). Update on regulation of GHRH and its actions on GH secretion in health and disease. Reviews in endocrine & metabolic disorders, 26(3), 305–320. https://doi.org/10.1007/s11154-025-09943-y
- Ben-Shlomo, A., & Melmed, S. (2010). Pituitary somatostatin receptor signaling. Trends in endocrinology and metabolism: TEM, 21(3), 123–133. https://doi.org/10.1016/j.tem.2009.12.003
- Olarescu NC, Gunawardane K, Hanson TK, et al. Normal Physiology of Growth Hormone in Normal Adults. [Updated 2025 Apr 18]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279056/
Explore our complete catalog of high-purity, third-party tested research compounds by visiting our main shop page for all your laboratory needs.
Additional information
| Size | 5 MG |
|---|
Related products
-
RT-GLP3
Price range: $150.00 through $200.00Select options This product has multiple variants. The options may be chosen on the product page -
-
-
Reviews
There are no reviews yet.